EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial

Nutzen von Chemoradiotherapie versus Chemotherapie nach Induktionstherapie zur Konversion nicht resektabler in resektable Pankreaskarzinome: die randomisierte CONKO-007-Studie

Rainer Fietkau iD, Michael Ghadimi iD, Robert Grützmann, Uwe A Wittel, Lutz Jacobasch, Waldemar Uhl, Roland S Croner, Wolf Otto Bechstein iD, Ulf Peter Neumann iD, Dirk Waldschmidt, Stefan Boeck iD, Nicolas Moosmann und 12 weitere

Journal of Clinical Oncology · 20.10.2025 · 43 (30) · 3266-3278

DOI: 10.1200/jco-24-01502 ↗

Auf einen Blick

Bei nicht resektablem Pankreaskarzinom erhöhte Chemoradiotherapie nach Induktionschemotherapie die R0-Resektionsrate nur bei operierten Patient:innen, nicht insgesamt. Ein Überlebensvorteil zeigte sich nicht.

Fragestellung

Verbessert Chemoradiotherapie nach Induktionschemotherapie bei nicht resektablem Pankreaskarzinom die R0-Resektionsrate gegenüber fortgesetzter Chemotherapie allein?

Methode

Offene, multizentrische, investigator-initiierte Phase-III-RCT; 525 eingeschlossene Patient:innen, 336 ohne Progress randomisiert; medianes Follow-up 76 Monate.

Ergebnisse

Primärer Endpunkt: overall R0-Resektionsrate 25 % (43/169) unter CRT vs. 18 % (30/167) unter Chemotherapie; P = .113. In der operierten Subgruppe: 69,4 % vs. 50,0 %; P = .04. OS ohne Unterschied: HR 0,937 (95 %-KI 0,747–1,174); P = .57.

Einschränkungen

Primärer Endpunkt während der Studie nach Interimsanalyse von OS auf R0-Resektion geändert; langsame Rekrutierung.

Schlussfolgerung der Autor:innen

Obwohl die Gesamt-R0-Resektionsrate und das Überleben nicht verbessert wurden, ermöglicht CRT bei operierten Patient:innen häufiger eine R0-Resektion als Chemotherapie allein.

Kernaussagen

  • Gesamt-R0-Resektion: 25 % mit CRT vs. 18 % mit Chemotherapie
  • Bei operierten Patient:innen: 69,4 % vs. 50,0 % R0-Resektionen
  • Kein Unterschied im Gesamtüberleben: HR 0,937 (95 %-KI 0,747–1,174)

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.10.2025. Verfasst von Rainer Fietkau und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Induction Chemotherapy, Chemoradiotherapy. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 30 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To determine the benefit, measured as complete removal of a tumor so that no tumor cells are detectable during histopathologic examination of the resection margin (R0 resection rate), of induction chemotherapy plus chemoradiotherapy (CRT) compared with chemotherapy alone for unresectable pancreatic tumors. PATIENTS AND METHODS CONKO-007, an investigator-initiated open-label, multicentric, phase III randomized clinical trial, enrolled 525 patients with unresectable tumors, and 495 patients received induction chemotherapy (402 with fluorouracil, irinotecan, and oxaliplatin [FOLFIRINOX] and 93 with gemcitabine). Patients without progression after 3 months of induction chemotherapy (n = 336) were randomly assigned for continuation of the same chemotherapy (n = 167) or CRT (n = 169; 50.4Gy concurrently with gemcitabine). Resectability was centrally reassessed by a panel of surgeons. Surgery was recommended if possible. After an interim analysis, the primary end point was changed from overall survival (OS) to overall R0 resection rate because of slow recruitment. The median follow-up was 76 months. Important planned secondary end points were R0 resection rate in the surgically treated population and OS. RESULTS The primary end point (overall R0 resection rate) was not significantly different between treatment arms with 25% (43 of 169) in the CRT arm versus 18% in the chemotherapy arm (30 of 167; P = .113). Secondary end point analysis showed that surgery was performed equally often ( P = .91); R0 resection rate in patients who underwent surgery was higher after CRT, 69.4% (43 of 62) compared with chemotherapy alone: 50.0% (30 of 60 patients, P = .04). Other parameters of resection (ratio of R0/R1/R2/no resection) also favored CRT ( P = .02). No difference in OS was seen between treatment arms (hazard ratio [HR], 0.937 [95% CI, 0.747 to 1.174]; P = .57; randomly assigned intention-to-treat patients). Surgery was associated with longer OS ( P < .001, HR, 0.525 [95% CI, 0.408 to 0.676]). CONCLUSION Although not improving overall R0 resection rate or survival, CRT enables a R0 resection in surgically treated patients more often than chemotherapy alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsInduction ChemotherapyChemoradiotherapyHumansMaleFemaleMiddle AgedAgedIrinotecanDeoxycytidineGemcitabineAdultFluorouracilOxaliplatinLeucovorinPancreatectomy

Substanzen

IrinotecanDeoxycytidineGemcitabineFluorouracilOxaliplatinLeucovorinfolfirinox

Autor:innen und Institutionen

  • Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
  • National Center for Tumor Diseases (NCT), NCT WERA, a partnership between DKFZ, and the universities and university hospitals in Würzburg, Erlangen, Regensburg and Augsburg, Germany.
  • Department of General, Visceral and Pediatric Surgery, Medical Center, Georg-August-University Göttingen, Göttingen, Germany.
  • Department of Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Department for General- and Visceral Surgery, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany.

ORCID-Profile: Rainer Fietkau, Michael Ghadimi, Wolf Otto Bechstein, Ulf Peter Neumann, Stefan Boeck, Anke C Reinacher-Schick, Henriette Golcher, Dorota Lubgan, Annett Kallies, Markus Hecht

Zitieren

APA

Fietkau, R., Ghadimi, M., Grützmann, R., Wittel, U. A., Jacobasch, L., Uhl, W., Croner, R. S., Bechstein, W. O., Neumann, U. P., Waldschmidt, D., Boeck, S., Moosmann, N., Reinacher-Schick, A. C., Golcher, H., Adler, W., Semrau, S., Lubgan, D., Kallies, A., Hecht, M., …, & CONKO Study Group (2025). Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial. Journal of Clinical Oncology, 43(30), 3266-3278. https://doi.org/10.1200/jco-24-01502

Vancouver

Fietkau R, Ghadimi M, Grützmann R, Wittel UA, Jacobasch L, Uhl W, et al. Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial. Journal of Clinical Oncology. 2025;43(30):3266-3278. doi:10.1200/jco-24-01502

BibTeX
@article{Fietkau2025,
  author = {Fietkau, Rainer and Ghadimi, Michael and Grützmann, Robert and Wittel, Uwe A and Jacobasch, Lutz and Uhl, Waldemar and Croner, Roland S and Bechstein, Wolf Otto and Neumann, Ulf Peter and Waldschmidt, Dirk and Boeck, Stefan and Moosmann, Nicolas and Reinacher-Schick, Anke C and Golcher, Henriette and Adler, Werner and Semrau, Sabine and Lubgan, Dorota and Kallies, Annett and Hecht, Markus and Tischoff, Iris and Tannapfel, Andrea and Frey, Benjamin and Oettle, Helmut and CONKO Study Group, CONKO Study Group},
  title = {Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {30},
  pages = {3266--3278},
  doi = {10.1200/jco-24-01502}
}
Kostenlos starten →